Calcitonin intranasal - West Pharmaceutical Services

Drug Profile

Calcitonin intranasal - West Pharmaceutical Services

Alternative Names: Salcatonin intranasal - West Pharmaceutical Services

Latest Information Update: 04 Feb 2008

Price : $50

At a glance

  • Originator West Pharmaceutical Services Drug Delivery and Clinical Research Centre
  • Class
  • Mechanism of Action Calcitonin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 11 Nov 2003 Calcitonin intranasal is available for licensing (
  • 20 Sep 2000 No-Development-Reported for Postmenopausal osteoporosis in United Kingdom (Intranasal)
  • 02 Jul 1998 Phase-I clinical trials for Postmenopausal osteoporosis in United Kingdom (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top